Eos Energy Enterprises Inc vs GeneDx Holdings Corp — how do they compare? Eos Energy Enterprises Inc trades at $2.65 (market cap $1.01B), while GeneDx Holdings Corp trades at $69.49 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2× Eos Energy Enterprises Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and GeneDx Holdings Corp for 19 Days on average.
| EOSE | WGS | |
|---|---|---|
Market Cap | $1.01B | $2.02B |
Volume | 39,626,541 | 734,640 |
Sector | Industrials | Health |
52-Week High | $19.19 | $167.51 |
52-Week Low | $2.77 | $34.51 |
Typical Hold Time | 16 Days | 19 Days |
Enterprise Value | $1.34B | $2.05B |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.645, down 14.68% in the last session, reflecting significant volatility amid mixed quarterly results. The company shows rapid revenue growth but deep losses, with a -246.76% net income margin in 2026. Recent developments include a $87 million DOE loan advance and a partnership with Google for a West Virginia energy project, highlighting growth potential in long-duration energy storage.
The outlook is bifurcated: strong revenue growth and strategic partnerships offer upside, but persistent losses and high debt-to-asset ratio of 91.87% pose substantial risks. Analyst consensus is cautious with a $7.10 price target, suggesting 168% potential upside, yet the bearish technical signal and negative cash flows from operations warrant careful monitoring of execution and funding needs.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →